申请人:Sterling Drug Inc.
公开号:US04361569A1
公开(公告)日:1982-11-30
3-(Hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof is useful as a cardiotonic agent. 3-Hydroxy-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone is prepared by autoclaving a mixture of a sodium or potassium lower-alkoxide, a lower-alkanol and 3-(chloro or bromo)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone and acidifying the reaction mixture. 3-Hydroxymethyl-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone is prepared by reacting 6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone with excess formaldehyde at an acidic pH. Said 3-(hydroxy or hydroxymethyl)-6-methyl-5-(4-pyridinyl)-2(1H)-pyridinone or pharmaceutically acceptable acid-addition salt thereof is disclosed as the active ingredient in cardiotonic compositions for increasing cardiac contractility and in the method for increasing cardiac contractility in a patient requiring such treatment.
3-(羟基或羟甲基)-6-甲基-5-(4-吡啶基)-2(1H)-吡啶酮或其药学上可接受的酸盐加成物作为一种心脏强心剂具有用途。3-羟基-6-甲基-5-(4-吡啶基)-2(1H)-吡啶酮是通过在钠或钾的低级烷氧化物、低级醇和3-(氯或溴)-6-甲基-5-(4-吡啶基)-2(1H)-吡啶酮的混合物中进行高压灭菌并使反应混合物酸化制备的。3-羟甲基-6-甲基-5-(4-吡啶基)-2(1H)-吡啶酮是通过在酸性pH下使6-甲基-5-(4-吡啶基)-2(1H)-吡啶酮与过量甲醛反应制备的。所述的3-(羟基或羟甲基)-6-甲基-5-(4-吡啶基)-2(1H)-吡啶酮或其药学上可接受的酸盐加成物被披露为心脏强心剂组合物的活性成分,用于增加心脏收缩力并用于需要该治疗的患者的增加心脏收缩力的方法。